UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1109-13
Program Prior Authorization/Notification - tobramycin inhalation
solution/powder
Medication* Bethkis®, Kitabis® Pak¥, TOBI™ Nebulizer Solution and TOBI®
Podhaler™, tobramycin solution for inhalation
* This list is subject to change
¥ Kitabis Pak is excluded from coverage for the majority of our benefits.
P&T Approval Date 5/2013, 2/2014, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019, 2/2020,
2/2021, 2/2022, 2/2023, 9/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Bethkis (tobramycin) is an inhaled aminoglycoside antibacterial indicated for the management of
cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). Safety and efficacy
have not been demonstrated in patients under the age of six years, patients with a forced
expiratory volume in less than one second (FEV ) <40% or >80% predicted, or patients colonized
1
with Burkholderia cepacia (B. cepacia). Bethkis is administered by inhalation using a hand-held
PARI LC Plus® Reusable Nebulizer with a PARI Vios Air compressor. After 28 days of therapy,
patients should stop Bethkis therapy for the next 28 days, and then resume therapy for the next 28
day on and 28 day off cycle.3
TOBI (tobramycin) and tobramycin inhalation solution are aminoglycoside antibacterials
indicated for the management of CF patients with P. aeruginosa. Safety and efficacy have not
been demonstrated in patients under the age of 6 years, patients with FEV <25% or >75%
1
predicted, or patients colonized with B. cepacia. TOBI is specifically formulated for inhalation
using the DeVilbiss® Pulmo-Aide® air compressor and PARI LC Plus® Reusable Nebulizer. After
28 days of therapy, patients should stop TOBI therapy for the next 28 days, and then resume
therapy for the next 28 day on and 28 day off cycle.1, 5
TOBI Podhaler (tobramycin) is an antibacterial aminoglycoside indicated for the management of
CF patients with P. aeruginosa. Safety and efficacy have not been demonstrated in patients under
the age of 6 years, patients with FEV <25% or >80%, or patients colonized with B. cepacia. The
1
contents of TOBI Podhaler capsules are only for oral inhalation and should only be used with the
Podhaler device. After 28 days of therapy, patients should stop TOBI therapy for the next 28
days, and then resume therapy for the next 28 day on and 28 day off cycle.2
Kitabis Pak (co-packaging of tobramycin inhalation solution and PARI LC Plus® Reusable
Nebulizer) is an aminoglycoside antibacterial drug indicated for the management of CF in
adults and pediatric patients 6 years of age and older with P. aeruginosa. Safety and efficacy
have not been demonstrated in patients under the age of 6 years, patients with FEV <25% or
1
>75% predicted, or patients colonized with B. cepacia. After 28 days of therapy, patients
should stop Kitabis therapy for the next 28 days, and then resume therapy for the next 28 day
on and 28 day off cycle.4
Members will be required to meet the coverage criteria below.
© 2024 UnitedHealthcare Services, Inc.
1
2. Coverage Criteriaa:
A. Initial Authorization
1. Bethkis, Kitabis Pak, TOBI Solution for Inhalation, TOBI Podhaler, or tobramycin
solution for inhalation will be approved based on both of the following criteria:
a. One of the following:
(1) Diagnosis of cystic fibrosis (CF)
-OR-
(2) Both of the following:
(a) Diagnosis of noncystic fibrosis bronchiectasis
-AND-
(b) One of the following:
i. Three or more exacerbations per year
-OR-
ii. Two or more exacerbations requiring hospitalization per year
-AND-
b. Lung infection with positive culture demonstrating Pseudomonas aeruginosa
infection
Authorization will be issued for 12 months
B. Reauthorization
1. Bethkis, Kitabis Pak, TOBI Solution for Inhalation, TOBI Podhaler, or
tobramycin solution for inhalation will be approved based on the following criterion:
a. Documentation of positive clinical response to Bethkis, Kitabis Pak, TOBI
Nebulizer Solution, TOBI Podhaler, or tobramycin solution for inhalation therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Not all tobramycin products are covered. Refer to the most current UHC prescription drug list to
identify covered products.
• Exclusion: Kitabis Pak is excluded from coverage for the majority of our benefits.
4. References:
1. TOBI Inhalation Solution [package insert]. East Hanover, NJ: Mylan Pharmaceuticals; February
2023.
2. TOBI Podhaler [package insert]. San Carlos, CA: Mylan Pharmaceuticals Inc.; February 2023.
3. Bethkis [package insert]. Woodstock, Illinois: Chesi USA, Inc.; February 2023.
4. Kitabis Pak [package insert]. Woodstock, Illinois: Catalent Pharma Solutions, LLC; April 2023.
5. Tobramycin Inhalation Solution [package insert]. Sellersville, PA.: Teva Pharmaceuticals USA;
October 2023.
6. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for
acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest.
2006;130(5):1503-1510. doi:10.1378/chest.130.5.1503
7. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for
the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. Published 2017 Sep
9. doi:10.1183/13993003.00629-2017
8. Spencer S, Felix LM, Milan SJ, et al. Oral versus inhaled antibiotics for bronchiectasis. Cochrane
Database Syst Rev. 2018;3(3):CD012579. Published 2018 Mar 27.
doi:10.1002/14651858.CD012579.pub2
9. Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in
children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand
guidelines [published correction appears in Med J Aust. 2015 Feb 16;202(3):130]. Med J Aust.
2015;202(1):21-23. doi:10.5694/mja14.00287
10. Chang AB, Bell SC, Byrnes CA, et al. Thoracic Society of Australia and New Zealand (TSANZ)
position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents
and adults in Australia and New Zealand. Respirology. 2023;28(4):339-349.
doi:10.1111/resp.14479
Laska IF, Crichton ML, Shoemark A, Chalmers JD. The efficacy and safety of inhaled antibiotics
for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet
Respir Med. 2019;7(10):855-869. doi:10.1016/S2213-2600(19)30185-7
Program Prior Authorization/Notification – Bethkis (tobramycin inhalation
solution), TOBI Nebulizer Solution (tobramycin inhalation solution)
and TOBI Podhaler (tobramycin inhalation powder)
Change Control
2/2014 Updated Background information and added criteria for Bethkis.
Removed reauthorization criteria and increased authorization to 60
months.
2/2015 Annual review. Added coverage for Kitabis Pak and tobramycin
inhalation solution. Updated background, clinical rules and references.
© 2024 UnitedHealthcare Services, Inc.
3
2/2016 Annual review with no changes to clinical content. Changed
authorization period to 12 months and added re-authorization period for
12 months. Updated references.
2/2017 Annual review. No changes to coverage criteria.
2/2018 Annual review. No changes to coverage criteria. Updated reference.
2/2019 Annual review. No changes to coverage criteria. Updated background
and references.
2/2020 Annual review. Updated background and references. No changes to
coverage criteria.
2/2021 Annual review. Updated references. No changes to coverage criteria.
Notation of exclusion for Kitabis Pak from the majority of our benefits.
2/2022 Annual review without changes to coverage criteria. Updated
background and references.
2/2023 Annual review without changes to coverage criteria. Added state
mandate footnote and updated references.
9/2023 Added coverage criteria for noncystic fibrosis bronchiectasis with
recurrent exacerbations. Updated references.
9/2024 Annual review. No changes to coverage criteria. Updated references.
© 2024 UnitedHealthcare Services, Inc.
4